CKD 508
Alternative Names: CKD-508Latest Information Update: 15 Dec 2024
Price :
$50 *
At a glance
- Originator Chong Kun Dang
- Class Antihyperlipidaemics
- Mechanism of Action Cholesterol ester transfer protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Dyslipidaemias
Most Recent Events
- 14 Nov 2024 Chong Kun Dang initiates a phase I trial in Dyslipidaemias (In volunteers) in USA (PO, Tablet) (NCT06727396)
- 16 Jan 2024 Phase I development is ongoing for Dyslipidaemias (In volunteers) in United Kingdom (PO) (Chong Kun Dang pipeline, January 2024)
- 28 Aug 2023 No recent reports of development identified for phase-I development in Dyslipidaemias(In volunteers) in United Kingdom (PO)